CMPX vs. PCB, MGX, AGEN, IPSC, ADVM, IPHA, KOD, CHRS, FENC, and INMB
Should you be buying Compass Therapeutics stock or one of its competitors? The main competitors of Compass Therapeutics include PCB Bancorp (PCB), Metagenomi (MGX), Agenus (AGEN), Century Therapeutics (IPSC), Adverum Biotechnologies (ADVM), Innate Pharma (IPHA), Kodiak Sciences (KOD), Coherus BioSciences (CHRS), Fennec Pharmaceuticals (FENC), and INmune Bio (INMB).
Compass Therapeutics (NASDAQ:CMPX) and PCB Bancorp (NASDAQ:PCB) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, community ranking, institutional ownership, risk, earnings, media sentiment, dividends and valuation.
In the previous week, Compass Therapeutics had 18 more articles in the media than PCB Bancorp. MarketBeat recorded 21 mentions for Compass Therapeutics and 3 mentions for PCB Bancorp. Compass Therapeutics' average media sentiment score of 0.77 beat PCB Bancorp's score of 0.41 indicating that Compass Therapeutics is being referred to more favorably in the media.
68.4% of Compass Therapeutics shares are held by institutional investors. Comparatively, 33.0% of PCB Bancorp shares are held by institutional investors. 30.0% of Compass Therapeutics shares are held by company insiders. Comparatively, 25.0% of PCB Bancorp shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Compass Therapeutics has a beta of 0.92, meaning that its stock price is 8% less volatile than the S&P 500. Comparatively, PCB Bancorp has a beta of 0.65, meaning that its stock price is 35% less volatile than the S&P 500.
Compass Therapeutics presently has a consensus price target of $9.00, suggesting a potential upside of 462.50%. PCB Bancorp has a consensus price target of $17.00, suggesting a potential upside of 8.14%. Given Compass Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Compass Therapeutics is more favorable than PCB Bancorp.
PCB Bancorp has higher revenue and earnings than Compass Therapeutics. Compass Therapeutics is trading at a lower price-to-earnings ratio than PCB Bancorp, indicating that it is currently the more affordable of the two stocks.
Compass Therapeutics received 12 more outperform votes than PCB Bancorp when rated by MarketBeat users. Likewise, 72.73% of users gave Compass Therapeutics an outperform vote while only 48.00% of users gave PCB Bancorp an outperform vote.
PCB Bancorp has a net margin of 14.69% compared to Compass Therapeutics' net margin of 0.00%. PCB Bancorp's return on equity of 9.09% beat Compass Therapeutics' return on equity.
Summary
Compass Therapeutics beats PCB Bancorp on 10 of the 17 factors compared between the two stocks.
Get Compass Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CMPX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CMPX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Compass Therapeutics Competitors List
Related Companies and Tools
